BrightSpring Health Services/$BTSG
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About BrightSpring Health Services
BrightSpring Health Services Inc is a home and community-based healthcare services platform, focused on delivering complementary pharmacy and provider services to complex patients. Its platform delivers clinical services and pharmacy solutions across Medicare, Medicaid, and commercially insured populations. Its segments include Pharmacy Solutions, Provider Services, and others. It generates the majority of its revenue from the Pharmacy Solutions segment.
- Ticker
- $BTSG
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- -
- Headquarters
- Louisville, United States
- Website
- www.brightspringhealth.com
BTSG Metrics
BasicAdvanced
$14B
36.42
$1.84
1.78
-
Price and volume
Market cap
$14B
Beta
1.78
52-week high
$73.75
52-week low
$30.64
Average daily volume
2.5M
Financial strength
Current ratio
1.617
Quick ratio
1.208
Long term debt to equity
1.048
Total debt to equity
1.088
Interest coverage (TTM)
3.77%
Profitability
EBITDA (TTM)
704.645
Gross margin (TTM)
12.50%
Net profit margin (TTM)
2.69%
Operating margin (TTM)
3.51%
Effective tax rate (TTM)
17.08%
Management effectiveness
Return on assets (TTM)
5.43%
Return on equity (TTM)
15.54%
Valuation
Price to earnings (TTM)
36.418
Price to revenue (TTM)
0.905
Price to book
6.37
Price to tangible book (TTM)
-16.28
Price to free cash flow (TTM)
28.019
Free cash flow yield (TTM)
3.57%
Free cash flow per share (TTM)
2.397
Growth
Revenue change (TTM)
25.97%
Earnings per share change (TTM)
204.99%
3-year revenue growth (CAGR)
21.89%
3-year earnings per share growth (CAGR)
1.94%
What the Analysts think about BTSG
Analyst ratings (Buy, Hold, Sell) for BrightSpring Health Services stock.
Analyst projections of the future price of BrightSpring Health Services stock.
Bulls say / Bears say
Third-quarter revenue rose 26.4% year on year and adjusted EBITDA increased 42%; BrightSpring also raised its full-year 2026 revenue and EBITDA guidance. That points to strong near-term earnings momentum. (GlobeNewswire)
Specialty and infusion revenue grew 34% in the third quarter, with specialty prescription growth of 29% and 19 branded limited-distribution drug launches year to date. Continued launches and wider access to specialist medicines offer a further growth runway. (The Motley Fool)
Provider Services revenue rose 31% in the third quarter, while home-health average daily census was up 58%. This provides a second growth engine alongside pharmacy, supported by both branch expansion and acquired operations. (GlobeNewswire)
The Inflation Reduction Act is weighing on home and community pharmacy: revenue there fell 6% in the third quarter, and management expects an approximately $200 million full-year impact. This remains a meaningful headwind even as the wider pharmacy business grows. (The Motley Fool)
Pharmacy prescription volumes were flat for the first nine months of 2026, even as revenue per script rose 24%. That gap suggests reported pharmacy growth is relying heavily on drug and payer mix rather than more prescriptions dispensed. (GlobeNewswire)
Debt remains a financial risk: the June filing reported $2.25 billion of total debt, despite a $300 million paydown. Leverage had improved to 1.79 times by September, but the company still needs to manage a substantial debt load alongside its growth plans. (SEC, GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 30 Oct 2026.
BTSG Financial Performance
Revenues and expenses
BTSG Earnings Performance
Company profitability
Upcoming events
No upcoming events
BTSG News
AllArticlesVideos
Funds containing BTSG
AllUSDEURGBP
Fund name | Fund size | $BTSG weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.38% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.38% |
SPDR S&P 400 US Mid Cap$SPY4 | $6.4B | 0.34% |
SPDR S&P 400 US Mid Cap£SPX4 | $6.4B | 0.34% |
Vanguard Russell 2000 U.S. Small-Cap£VRSG | $3M | 0.30% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.